Hematopoietic stem cells with enhanced transplantability, ruxolitinib for refractory macrophage activation syndrome, and magrolimab in newly diagnosed acute myeloid leukemia
In this week's episode we'll learn more about enhanced transplant characteristics; targeting the JAK-STAT pathway with ruxolitinib in patients with adult-onset Still’s disease and macrophage activation syndrome; and a pair of trials demonstrating lack of benefit for the anti-CD47 monoclonal antibody magrolimab in newly diagnosed acute myeloid leukemia.
Featured Articles
Heterogeneity of high-potency multilineage hematopoietic stem cells and identification of “Super” transplantability
Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.